Hengrui Pharmaceutical announced that its subsidiary Fujian Shengdi Pharmaceutical Co., Ltd. has received the HRS-4139 “Drug Clinical Trial Approval Notice” approved and issued by the State Drug Administration and will conduct clinical trials for moderate to severe plaque psoriasis in the near future. HRS-4139 tablets are a Class 1 new drug independently developed by the company. No drugs with the same target have been approved for marketing at home or abroad. Up to now, the total R&D investment for related projects is about 20.4 million yuan. The drug still needs to complete clinical trials and pass review and approval before it can be marketed. There is uncertainty about development and marketing.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.